Olatoyosi Odenike

Olatoyosi Odenike

UNVERIFIED PROFILE

Are you Olatoyosi Odenike?   Register this Author

Register author
Olatoyosi Odenike

Olatoyosi Odenike

Publications by authors named "Olatoyosi Odenike"

Are you Olatoyosi Odenike?   Register this Author

71Publications

1665Reads

34Profile Views

Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutions.

Cancer 2018 12 5;124(24):4601-4609. Epub 2018 Oct 5.

Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.31769
Publisher Site
http://dx.doi.org/10.1002/cncr.31769DOI Listing
December 2018

How I treat the blast phase of Philadelphia chromosome-negative myeloproliferative neoplasms.

Blood 2018 11 17;132(22):2339-2350. Epub 2018 Oct 17.

Section of Hematology Oncology, Department of Medicine, University of Chicago Comprehensive Cancer Center, The University of Chicago Medicine, Chicago, IL.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/lookup/doi/10.1182/blood-2018-03
Publisher Site
http://dx.doi.org/10.1182/blood-2018-03-785907DOI Listing
November 2018

Novel Therapies for Myelofibrosis.

Curr Hematol Malig Rep 2017 12;12(6):611-624

Section of Hematology/Oncology, Department of Medicine, The University of Chicago, 5841 S. Maryland Ave, MC2115, Chicago, IL, 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-017-0403-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808510PMC
December 2017

Incorporating novel approaches in the management of MDS beyond conventional hypomethylating agents.

Hematology Am Soc Hematol Educ Program 2017 12;2017(1):460-469

Department of Medicine, Section of Hematology/Oncology, The University of Chicago, Chicago, IL; and The University of Chicago Comprehensive Cancer Center, Chicago, IL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2017.1.460DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142530PMC
December 2017

Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia.

Leuk Lymphoma 2017 09 20;58(9):1-7. Epub 2017 Feb 20.

b Department of Medicine , Section of Hematology/Oncology, The University of Chicago Medicine , Chicago , IL , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2017.1289524DOI Listing
September 2017

Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.

J Clin Oncol 2017 Aug 9;35(24):2745-2753. Epub 2017 May 9.

Mikkael A. Sekeres and Aziz Nazha, Cleveland Clinic, Cleveland; Clara D. Bloomfield, The Ohio State University Comprehensive Cancer Center, Columbus, OH; Megan Othus and Anna Moseley, SWOG Statistical Center; Min Fang and Frederick R. Appelbaum, Fred Hutchinson Cancer Research Center, Seattle, WA; Alan F. List, H. Lee Moffitt Cancer Center, Tampa, FL; Olatoyosi Odenike, University of Chicago, Chicago; Mario R. Velasco, Heartland NCORP/Cancer Care Specialists of Central Illinois, Decatur, IL; Richard M. Stone, Dana Farber Cancer Institute; Eyal C. Attar, Massachusetts General Hospital, Boston, MA; Steven D. Gore, Yale University, New Haven, CT; Mark R. Litzow, Mayo Clinic, Rochester, MN; Rena Buckstein, Sunnybrook Health Sciences Centre, Toronto; Elina K. Cook, Alyssa H. Cull, and Michael J. Rauh, Queen's University, Kingston, Ontario, Canada; Diane Roulston, University of Michigan, Ann Arbor, MI; Yanming Zhang, Memorial Sloan-Kettering Cancer Center, New York, NY; Rakesh Gaur, Kansas City National Cancer Institute Community Oncology Research Program, Prairie Village, KS; Ehab Atallah, Medical College of Wisconsin, Milwaukee, WI; and Harry P. Erba, University of Alabama, Birmingham, AL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.66.2510DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562170PMC
August 2017

Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies.

J Hematol Oncol 2016 12 8;9(1):137. Epub 2016 Dec 8.

Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13045-016-0367-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5146859PMC
December 2016

Blast-phase myeloproliferative neoplasms: risk factors and treatment approaches.

Expert Rev Hematol 2016 Jul 29:1-9. Epub 2016 Jul 29.

a Department of Medicine, Section of Hematology/Oncology , University of Chicago , Chicago , IL , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2016.1210004DOI Listing
July 2016

Myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms: an update on risk stratification, molecular genetics, and therapeutic approaches including allogeneic hematopoietic stem cell transplantation.

Am Soc Clin Oncol Educ Book 2015 :e398-412

From the Section of Hematology/Oncology, and the Comprehensive Cancer Center, The University of Chicago, Chicago, IL; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy; Moffitt Cancer Center, Tampa, FL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2015.35.e398DOI Listing
February 2016

Defining and Treating Older Adults with Acute Myeloid Leukemia Who Are Ineligible for Intensive Therapies.

Front Oncol 2015 14;5:280. Epub 2015 Dec 14.

Section of Hematology/Oncology, Department of Medicine, The University of Chicago , Chicago, IL , USA.

View Article

Download full-text PDF

Source
http://journal.frontiersin.org/Article/10.3389/fonc.2015.002
Publisher Site
http://dx.doi.org/10.3389/fonc.2015.00280DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4677344PMC
December 2015

Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia.

N Engl J Med 2015 Sep;373(10):920-8

From the Department of Hematology, University Hospital of Bern and University of Bern, Bern, Switzerland (G.M.B., E.O.L., M.D.); the Department of Hematology, School of Medicine, Cardiff University, Cardiff, United Kingdom (O.G.O.); Upstate Oncology Associates, Greenville, SC (G.S.); the Section of Hematology and Oncology, University of Chicago, Chicago (O.O.); the Divisions of Hematologic Malignancies and Hematology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore (M.A.M.); the Department of Hematology, University Hospital Essen, Essen, Germany (A.R.); and Geron, Menlo Park (B.B., M.S.), and the Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Gehr Family Center for Leukemia Research, Duarte (D.S.S.) - both in California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1503479DOI Listing
September 2015

Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies.

Curr Hematol Malig Rep 2015 Jun;10(2):112-7

Department of Medicine, Section of Hematology/Oncology, The University of Chicago, 5841 S. Maryland Ave., MC 2115, Chicago, IL, 60637, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007%2Fs11899-015-02
Web Search
http://link.springer.com/10.1007/s11899-015-0259-0
Publisher Site
http://dx.doi.org/10.1007/s11899-015-0259-0DOI Listing
June 2015

Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology.

J Clin Oncol 2015 Mar 20;33(7):786-809. Epub 2015 Jan 20.

Gregory Masters, Helen F. Graham Cancer Center, Newark, DE; Lada Krilov and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Howard H. Bailey, University of Wisconsin Hospital and Clinics, Madison, WI; Marcia S. Brose, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Harold Burstein and Lisa R. Diller, Dana-Farber Cancer Institute; Don S. Dizon, Massachusetts General Hospital, Boston, MA; Howard A. Fine, New York University Langone Medical Center; Gary K. Schwartz, Columbia University Medical Center, New York, NY; Gregory P. Kalemkerian, University of Michigan Health System; Sandra L. Wong, University of Michigan, Ann Arbor, MI; Mark Moasser, University of California San Francisco School of Medicine; Charles J. Ryan and Alan P. Venook, University of California San Francisco, San Francisco; Steven J. O'Day, Beverly Hills Health Center, Beverly Hills, CA; Michael N. Neuss, Vanderbilt-Ingram Cancer Center, Nashville, TN; Olatoyosi Odenike, University of Chicago; and Jyoti D. Patel, Northwestern University, Chicago, IL.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/01/16/JCO.2014.59
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.59.9746
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.59.9746DOI Listing
March 2015

Beyond JAK inhibitor therapy in myelofibrosis.

Hematology Am Soc Hematol Educ Program 2013 ;2013:545-52

1Department of Medicine, Section of Hematology/Oncology, The University of Chicago, Chicago, IL; and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2013.1.545DOI Listing
July 2014

Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.

Clin Cancer Res 2014 Jan 31;20(2):490-8. Epub 2013 Oct 31.

Authors' Affiliations: The University of Chicago; Decatur Memorial Hospital, Decatur; Illinois Cancer Care, Peoria; Loyola University Medical Center, Maywood, Illinois; University of California, San Francisco, San Francisco; City of Hope, Duarte, California; University of Michigan Medical Center, Ann Arbor, Michigan; Medical College of Wisconsin, Milwaukee, Wisconsin; and National Cancer Institute, Rockville, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1311DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4310865PMC
January 2014

Age-related differences in disease characteristics and clinical outcomes in polycythemia vera.

Leuk Lymphoma 2013 Sep 8;54(9):1989-95. Epub 2013 Jan 8.

Medicine and Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.3109/10428194.2012.75
Publisher Site
http://dx.doi.org/10.3109/10428194.2012.759656DOI Listing
September 2013

A 32-year-old man with persistent cough, shortness of breath, eosinophilic pneumonia, and peripheral blood eosinophilia. Myeloid neoplasm associated with eosinophilia and platelet-derived growth factor receptor-alpha rearrangement.

Chest 2012 Dec;142(6):1680-1683

Department of Medicine, Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL; The University of Chicago Comprehensive Cancer Center, University of Chicago Medical Center, Chicago, IL. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00123692126070
Publisher Site
http://dx.doi.org/10.1378/chest.12-0652DOI Listing
December 2012

Late-phase investigational approaches for the treatment of relapsed/refractory acute myeloid leukemia.

Expert Opin Pharmacother 2012 Oct 13;13(15):2171-87. Epub 2012 Sep 13.

University of North Carolina, Chapel Hill, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14656566.2012.724061DOI Listing
October 2012

Influence of related donor age on outcomes after peripheral blood stem cell transplantation.

Cytotherapy 2012 Jul 2;14(6):707-15. Epub 2012 May 2.

Biological Sciences Division, Department of Pathology, Section of Blood Bank and Transfusion Medicine, University of Chicago, Chicago, Illinois 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/14653249.2012.681041DOI Listing
July 2012

Myelodysplastic syndromes.

Clin Lab Med 2011 Dec 10;31(4):763-84. Epub 2011 Oct 10.

Department of Medicine, Section of Hematology/Oncology, University of Chicago, 5841 South Maryland, MC2115, Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cll.2011.08.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340482PMC
December 2011

The dawn of the molecular era of the myelodysplastic syndromes.

N Engl J Med 2011 Jun;364(26):2545-6

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMe1102921DOI Listing
June 2011

Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet?

Semin Oncol 2011 Apr;38(2):196-214

Department of Medicine, The University of Chicago, Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2011.01.010DOI Listing
April 2011

Emerging role of the histone deacetylase inhibitor romidepsin in hematologic malignancies.

Expert Opin Pharmacother 2010 Dec;11(18):3073-84

Department of Medicine, University of Chicago Cancer Research Center, IL 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14656566.2010.534779DOI Listing
December 2010

Leukaemogenesis: more than mutant genes.

Nat Rev Cancer 2010 Jan;10(1):23-36

Department of Medicine, University of Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nrc2765
Publisher Site
http://dx.doi.org/10.1038/nrc2765DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2972637PMC
January 2010

Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia.

Leuk Lymphoma 2009 Jan;50(1):85-91

Section of Hematology/Oncology, Department of Medicine and the Cancer Research Center, The University of Chicago, Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428190802626624DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3617055PMC
January 2009

DNA repair genes, electromagnetic fields and susceptibility to acute leukemia?

Leuk Lymphoma 2008 Dec;49(12):2233-4

Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637-1470, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428190802573123DOI Listing
December 2008

Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation.

Biol Blood Marrow Transplant 2008 Nov;14(11):1209-16

Section of Hematology/Oncology, Department of Medicine, University of Chicago, The University of Chicago Cancer Research Center, Chicago, Illinois 60637, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S108387910800349
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2008.08.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668514PMC
November 2008

Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.

Invest New Drugs 2008 Jun 24;26(3):233-9. Epub 2008 Jan 24.

Section of Hematology/Oncology, Department of Medicine, University of Chicago Medical Center, 5841 S. Maryland Avenue, MC 2115, Chicago, IL 60637-1470, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-008-9115-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283497PMC
June 2008

Conventional and new treatment options for myelofibrosis with myeloid metaplasia.

Semin Oncol 2005 Aug;32(4):422-31

Department of Medicine, Section of Hematology/Oncology, University of Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2005.06.014DOI Listing
August 2005

A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases.

Cancer Chemother Pharmacol 2004 Dec 2;54(6):553-61. Epub 2004 Sep 2.

Section of Hematology/Oncology, Department of Medicine, University of Chicago, 5841 S. Maryland Avenue, MC 2115, Chicago, IL 60637-1470, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00280-004-0857-3
Publisher Site
http://dx.doi.org/10.1007/s00280-004-0857-3DOI Listing
December 2004